Genpact Named a Leader in Life Sciences Digital Services for Mid-Market Enterprises in 2024 Everest Group PEAK Matrix® Assessment
Genpact (NYSE: G) has been named a Leader in Everest Group's inaugural Life Sciences Digital Services for Mid-Market Enterprises 2024 PEAK Matrix® Assessment. This recognition highlights Genpact's expertise in delivering innovative solutions to mid-market life sciences companies. The assessment evaluated 26 global providers based on vision, capability, and market impact.
Genpact's leadership is underpinned by excellence in key services, including:
- Data Analytics and Insights: AI-powered analytics for better decision-making
- Supply Chain Resilience: Optimizing the entire value chain
- Regulatory Compliance: Navigating regulatory complexity
- Patient-Centric Experiences: Enhancing patient engagement and outcomes
This recognition validates Genpact's commitment to improving global health by accelerating time-to-market for drugs and devices.
Genpact (NYSE: G) è stata nominata Leader nell'inaugurazione della valutazione PEAK Matrix® dell'Everest Group sui Servizi Digitali per le Scienze della Vita per le Medie Imprese 2024. Questo riconoscimento evidenzia l'esperienza di Genpact nell'offrire soluzioni innovative alle aziende di scienze della vita di medie dimensioni. La valutazione ha analizzato 26 fornitori globali in base a visione, capacità e impatto sul mercato.
Il successo di Genpact è supportato dall'eccellenza nei servizi chiave, tra cui:
- Analisi dei Dati e Insights: Analisi potenziata dall'IA per migliorare il processo di decisione
- Resilienza della Catena di Fornitura: Ottimizzazione dell'intera catena del valore
- Conformità Normativa: Navigazione nella complessità normativa
- Esperienze Centrate sul Paziente: Miglioramento del coinvolgimento e dei risultati dei pazienti
Questo riconoscimento convalida l'impegno di Genpact nel migliorare la salute globale accelerando il tempo di commercializzazione di farmaci e dispositivi.
Genpact (NYSE: G) ha sido nombrada Líder en la evaluación inaugural PEAK Matrix® de Everest Group sobre Servicios Digitales en Ciencias de la Vida para Empresas de Mercado Medio 2024. Este reconocimiento destaca la experiencia de Genpact en ofrecer soluciones innovadoras a empresas de ciencias de la vida de mercado medio. La evaluación analizó a 26 proveedores globales en base a visión, capacidad e impacto en el mercado.
El liderazgo de Genpact se fundamenta en la excelencia en servicios clave, que incluyen:
- Analítica de Datos e Insights: Analítica impulsada por IA para una mejor toma de decisiones
- Resiliencia de la Cadena de Suministro: Optimización de toda la cadena de valor
- Cumplimiento Regulatorio: Navegando la complejidad regulatoria
- Experiencias Centradas en el Paciente: Mejora del compromiso y los resultados del paciente
Este reconocimiento valida el compromiso de Genpact de mejorar la salud global acelerando el tiempo de comercialización de medicamentos y dispositivos.
Genpact (NYSE: G)는 에버레스트 그룹의 중견 기업을 위한 생명 과학 디지털 서비스에 대한 첫 번째 PEAK Matrix® 평가에서 리더로 선정되었습니다. 이 인식은 중견 생명 과학 기업에 혁신적인 솔루션을 제공하는 Genpact의 전문성을 강조합니다. 이 평가는 비전, 역량 및 시장 영향력을 기준으로 26개의 글로벌 공급자를 평가했습니다.
Genpact의 리더십은 핵심 서비스에서의 뛰어난 성과에 기반하고 있습니다. 주요 서비스는 다음과 같습니다:
- 데이터 분석 및 통찰력: 더 나은 의사 결정을 위한 AI 기반 분석
- 공급망 회복력: 전체 가치 사슬 최적화
- 규제 준수: 복잡한 규제 탐색
- 환자 중심 경험: 환자 참여 및 결과 향상
이 인식은 Genpact가 의약품 및 장치의 시장 출시 시간을 단축하여 글로벌 건강을 개선하려는 의지를 검증합니다.
Genpact (NYSE: G) a été désignée Leader dans l'évaluation PEAK Matrix® inaugurale de l'Everest Group sur les Services Numériques en Sciences de la Vie pour les Entreprises de Taille Intermédiaire 2024. Cette reconnaissance met en avant l'expertise de Genpact dans la fourniture de solutions innovantes aux entreprises de sciences de la vie de taille intermédiaire. L'évaluation a examiné 26 fournisseurs mondiaux sur la base de leur vision, de leurs capacités et de leur impact sur le marché.
Le leadership de Genpact repose sur l'excellence de ses services clés, notamment :
- Analyse des Données et Insights: Analyse alimentée par l'IA pour une meilleure prise de décision
- Résilience de la Chaîne d'Approvisionnement: Optimisation de l'ensemble de la chaîne de valeur
- Conformité Réglementaire: Navigation dans la complexité réglementaire
- Expériences Axées sur le Patient: Amélioration de l'engagement et des résultats des patients
Cette reconnaissance valide l'engagement de Genpact à améliorer la santé mondiale en accélérant le délai de mise sur le marché des médicaments et des dispositifs.
Genpact (NYSE: G) wurde im Rahmen der Erstausgabe der PEAK Matrix®-Bewertung von Everest Group für Digitale Dienstleistungen im Bereich Life Sciences für den Mittelstand 2024 als Leader ausgezeichnet. Diese Anerkennung hebt das Fachwissen von Genpact hervor, innovative lösungen für mittelständische Unternehmen im Bereich Life Sciences bereitzustellen. Die Bewertung analysierte 26 globale Anbieter anhand von Vision, Fähigkeit und Markteinfluss.
Die Führungsstärke von Genpact beruht auf hervorragenden Leistungen in Schlüsselbereichen, darunter:
- Datenanalytik und Erkenntnisse: KI-gesteuerte Analytik für bessere Entscheidungsfindung
- Resilienz der Lieferkette: Optimierung der gesamten Wertschöpfungskette
- Regulatorische Compliance: Navigation durch regulatorische Komplexität
- Patientenzentrierte Erfahrungen: Verbesserung des Engagements und der Ergebnisse für Patienten
Diese Anerkennung bestätigt das Engagement von Genpact, die globale Gesundheit zu verbessern, indem die Markteinführungszeit für Arzneimittel und Medizinprodukte verkürzt wird.
- Recognized as a Leader in Everest Group's Life Sciences Digital Services for Mid-Market Enterprises 2024 PEAK Matrix® Assessment
- Demonstrated excellence in delivering key services such as data analytics, supply chain management, regulatory compliance, and patient-centric solutions
- Global client presence established through creative client engagement and innovative commercial constructs
- None.
Recognition highlights Genpact's commitment to delivering personalized support and innovative solutions to mid-market life sciences organizations
"Amid economic uncertainty, disrupted supply chains, and high customer expectations, it's more important than ever for life sciences companies to focus on AI innovation and operational resilience," said Sanjiv Tandon, Global Business Unit Leader, Life Sciences, Genpact. "Our deep industry expertise and customer-centric approach have made us a trusted partner in delivering transformative outcomes, and this leadership recognition validates our commitment to improving global health by accelerating the time-to-market for drugs and devices."
Everest Group assessed 26 life sciences digital services providers around the globe based on their vision, capability, and market impact. Genpact's leadership is underpinned by its excellence in delivering key services, including:
- Data Analytics and Insights: Leveraging AI-powered analytics to help life sciences companies uncover valuable insights for better decision-making, Genpact's digital solutions help improve patient experiences and outcomes, optimize sales strategies, and enhance marketing efforts.
- Supply Chain Resilience: In an industry where integrated sales and operations planning is critical, Genpact's supply chain management solutions and services optimize the entire value chain, from forecasting and network design to transportation and logistics, mitigating supply chain risks and improving operational efficiency.
- Regulatory Compliance: The regulatory landscape for life sciences continues to evolve, and compliance is essential. Genpact's regulatory affairs services help companies navigate regulatory complexity and compliance.
- Patient-Centric Experiences: With the shift towards patient-centric models, Genpact's advanced analytics and AI-driven customer experience solutions and expertise in digital therapeutics help companies enhance patient engagement, improve adherence, and deliver better health outcomes.
"Mid-market life sciences enterprises face unique challenges that distinguish them from their larger counterparts, necessitating distinct sourcing needs such as client intimacy, agility, and cost-effective innovation to stay competitive. Recognizing these specific needs, providers are tailoring their strategies to offer personalized support and innovative solutions, capitalizing on the increasing mid-market demand," said Durga Ambati, Practice Director, Everest Group. "Genpact's ability to creatively engage clients in strategic conversations, complemented by its willingness to explore innovative commercial constructs, has helped it to establish a global client presence and be recognized as a Leader in Everest Group's Life Sciences Digital Services for Mid-market Enterprises PEAK Matrix® Assessment 2024."
For more information about Genpact's life science solutions and services, visit: https://www.genpact.com/industries/healthcare-and-life-sciences/life-sciences
About Genpact
Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI.
Get to know us at genpact.com and on LinkedIn, X, YouTube, and Facebook.
MEDIA CONTACT:
Roopanki Kalra
Genpact Media Relations -
+91 9971634388
roopanki.kalra@genpact.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-named-a-leader-in-life-sciences-digital-services-for-mid-market-enterprises-in-2024-everest-group-peak-matrix-assessment-302248861.html
SOURCE Genpact
FAQ
What recognition did Genpact (NYSE: G) receive in the life sciences sector?
What key services does Genpact (NYSE: G) offer to mid-market life sciences companies?
How does Genpact (NYSE: G) contribute to improving global health in the life sciences sector?
What factors were considered in Everest Group's assessment of Genpact (NYSE: G)?
